HealthDay News — For postmenopausal breast cancer patients receiving aromatase inhibitors, oral osteoporosis therapy (OPT) is associated with improved survival, according to a study published online May 2 in Cancer.
Allan Lipton, MD, from the Penn State Hershey Medical Center, and colleagues enrolled 7576 postmenopausal women in the MA.27 phase 3 adjuvant trial. Patients were permitted bisphosphonates to prevent or treat osteopenia/osteoporosis and were followed for event-free and distant disease-free survival (EFS and DDFS).
The researchers found that osteoporosis was reported by 654 women (8.6%) at baseline and by 1294 women in total. At baseline, oral OPT was received by 10.8% of the women and by 36% in total. There were 693 EFS events (9.15%) and 321 DDFS events (4.2%) during a median follow-up of 4.1 years. There was no correlation noted for EFS or DDFS with osteoporosis. There were few EFS events before OPT initiation, with no substantial evidence of a time-differing effect on outcomes. OPT correlated with improved EFS and DDFS (hazard ratios for yes versus no, 0.67 and 0.57, respectively). There was no association for time-differing OPT with EFS. There was no correlation for OPT with incidence of visceral-only metastasis.
“Oral OPT, administered to postmenopausal breast cancer patients receiving adjuvant aromatase inhibitor therapy, was associated with improved EFS and DDFS; the time of OPT initiation (a time-dependent effect) did not affect the outcome,” the authors wrote.
Several authors disclosed financial ties to the pharmaceutical industry.
Lipton A, Chapman J-A W, Leitzel K, et al. Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27 [published online April 2017]. Cancer. doi:10.1002/cncr.30682